1. Development and validation of the Composite Asthma Severity Index—an outcome measure for use in children and adolescents 
Jeremy J. Wildfire, MS, Peter J. Gergen, MD, MPH, Christine A. Sorkness, PharmD, Herman E. Mitchell, PhD, Agustin Calatroni, MA, MS, Meyer Kattan, MD, CM, Stanley J. Szefler, MD, Stephen J. Teach, MD, MPH, Gordon R. Bloomberg, MD, Robert A. Wood, MD, Andrew H. Liu, MD, Jacqueline A. Pongracic, MD, James F. Chmiel, MD, MPH, Kathleen Conroy, MD, Yadira Rivera-Sanchez, MD, William W. Busse, MD, Wayne J. Morgan, MD, CM 
Journal of Allergy and Clinical Immunology 
Volume 129, Issue 3, Pages (March 2012)
DOI: /j.jaci
Copyright © Terms and Conditions

2. Fig 1 CASI development overview.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © Terms and Conditions

3. Fig 2
Determining independent domains of asthma severity: the 5 dimensions of CASI.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © Terms and Conditions

4. Fig 3
Scale properties of CASI: ACT, symptom days, and CASI distribution. CASI, symptom days, and ACT at recruitment (visit 1) and at the end of the study for subjects who attended each of 8 ACE study visits. The dashed line and shaded area show the mean ± one-half standard deviation. Annotated values are means (SD). The variances of ACT score and symptom days are lower at visit 8 (P < .001) while the change in variance for CASI is minimal (P = .08).
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © Terms and Conditions

5. Fig 4
External validation against an independent sample—effect of the ICATA intervention on symptom days and composite asthma severity. Values are adjusted for omalizumab dosing group, season, and study site. The first 12 weeks of the double-blind phase served as a wash-in period and were not included in analyses.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © Terms and Conditions